Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Jan 17, 2023 3:43pm
397 Views
Post# 35228964

Why is Onc going up?

Why is Onc going up?First of all! It is way underpriced.
They have two, phase 3 ready advancement possibilities.
one from stellar results alongside Roche ( tecentriq)....pancreatic cancer , FDA fast track approval 
The other being results alongside Pfizer for MBC
Either or both could be ( and should be) in negotiations with Onc.
either licensing partnership, or total buy out.
It's very possible Roche would buy the whole thing, Run with the panc cancer & owning Onc, would allow them the same contract in existence with Pfizer...on the Mbc
when a company is bought, the new owners get it all. The A.N. Partnership, The Pfizer first right of refusal.
the Car-t , results that after a booster shot of Pela, eliminated the cancer.
if you look closely at Onc " pipeline" There are about a dozen different trials on going, with various institutions & pharma collaborations.
could be worth billions


<< Previous
Bullboard Posts
Next >>